Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- Growth in Prescriptions of Prazaxa May Hit Snag Due to “Blue Letter”
September 26, 2011
- Why Generics’ Market Share Appears So Low in Japan; 20% Actually Means 35.7% if Overseas Calculation Method is Used
September 26, 2011
- 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
- Government Designates Fulvestrant as Ad-restricted Drug
September 21, 2011
- HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
- Price Settlement Rate Down to 73.9% of Sales in June, Close to Pre-emergency Recommendation Levels
September 19, 2011
- New METI Minister Edano Considers Drug Industry as “Highly Promising Area”
September 19, 2011
- FY2011 White Paper Calls For Reform toward “Participatory” Social Security System
September 19, 2011
- PMDA Expresses Distrust of MSD for Deviations from GCP in Trials of Gardasil
September 19, 2011
- Some Medical Institutions Still Demanding Full Payment, No Refund of Clinical Trial Costs
September 19, 2011
- Discussions Continue on Relief System for Victims of ADRs Due to Anticancer Drugs
September 19, 2011
- Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
- Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
- US FDA Issues Warning Letter Over GMP Violations by Daiichi Sankyo Subsidiary
September 15, 2011
- MHLW to Survey “Family Pharmacy” Function Toward Next Revision of Dispensing Fees
September 15, 2011
- US Proposes Elimination of Tariff on Drugs: TPP Talks
September 14, 2011
- MHLW to Continue to Promote Non-proprietary Name-based Brand Names for GE Drugs
September 14, 2011
- ”GMP Team” to Begin Mock GMP Inspections in Kinki Region from Next February
September 14, 2011
- MHLW Permits Ongoing Internet Sales of Reclassified Class 2 Drugs as Provisional Measure
September 13, 2011
- MHLW Minister Komiyama to Push Drug Industry Development Through Government-Private Sector Cooperation
September 13, 2011
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…